Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-559 + glyburide
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TAK-559 + glyburide is a combination of two oral antidiabetic agents. TAK-559 is a novel oxyiminoalkanoic acid derivative developed as an insulin-sensitizing agent. It acts as a dual agonist for human peroxisome proliferator–activated receptor gamma (PPARγ) and peroxisome proliferator–activated receptor alpha (PPARα), with partial agonist activity at PPARγ and slight activity at PPARδ, leading to improved insulin sensitivity[6]. Glyburide (also known as glibenclamide) is a second-generation sulfonylurea that lowers blood glucose by stimulating pancreatic beta cells to secrete insulin through closure of ATP-sensitive potassium channels (sulfonylurea receptor 1, SUR1)[5][1]. This combination may be investigated for synergistic effects in the management of type 2 diabetes mellitus.
- Brand names
- DiaBetaGlynase PresTabMicronase
- Other names
- glibenclamide
02
Targets
SUR1 (Sulfonylurea receptor 1)PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on TAK-559 + glyburide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-559 + glyburide.